The financials
Halozyme Therapeutics, Inc. by the numbers
Halozyme Therapeutics, Inc. (HALO) reported revenue of $377M in Q1 2026 (quarter ended March 31, 2026), up 42% from the same quarter a year earlier. That came with a gross margin of 79% and net income of $150M (40% of revenue). For the full year FY2025, revenue was $1.40B (+38% year on year) and net income $317M. Its largest product in 2026-Q1 was Royalty at $241M, 63% of the disclosed total, just ahead of Bulk R Hu PH20 at 19%.
| Income statement | Q1 2026 | Q1 2025 | Change |
|---|---|---|---|
| Revenue | $377M | $265M | +42% |
| Gross profit | $297M | $216M | +37% |
| Operating income | $185M | $142M | +30% |
| Net income | $150M | $118M | +27% |
| Diluted EPS | $1.22 | $0.93 | +31% |
| Product | Revenue | Share |
|---|---|---|
| Royalty | $241M | 63% |
| Bulk R Hu PH20 | $73M | 19% |
| Proprietary Products Sales | $42M | 11% |
| Device Partnered Products | $15M | 3.9% |
| Collaborative Agreements | $5.6M | 1.5% |
| Device Licensing And Development | $5.6M | 1.5% |
Business Segments
Revenue split by product segment, from SEC XBRL filings.
Latest period: Q1 2026Total $382.3M (+1.1%)
Bulk R Hu PH20 grew +172% year on yearUpfront Fees -100% year on year
Segment Latestquarter on quarteryear on year
- Royalty$240.7M$240.7MQoQ +2.0%year on year +43%+2.0%+43%
- Bulk R Hu PH20$73.5M$73.5MQoQ -year on year +172%-+172%
- Proprietary Products Sales$41.9M$41.9MQoQ -20%year on year +15%-20%+15%
- Device Partnered Products$15.1M$15.1MQoQ +59%year on year +2.6%+59%+2.6%
- Collaborative Agreements$5.6M$5.6MQoQ -77%year on year -70%-77%-70%
- Device Licensing And Development$5.6M$5.6MQoQ +40%year on year +64%+40%+64%
- Bulkr Hu PH20--QoQ -year on year ---
- Event Based Development And Regulatory Milestone And Other Fees--QoQ -year on year ---
- Sales Based Milestone$0.00$0.00QoQ -100%year on year -100%-100%-100%
- Upfront Fees$0.00$0.00QoQ -year on year -100%--100%
- Upfrontfees--QoQ -year on year ---